Success Metrics

Clinical Success Rate
72.5%

Based on 95 completed trials

Completion Rate
73%(95/131)
Active Trials
33(18%)
Results Posted
77%(73 trials)
Terminated
36(19%)

Phase Distribution

Ph not_applicable
7
4%
Ph phase_2
100
54%
Ph phase_4
11
6%
Ph phase_3
9
5%
Ph early_phase_1
4
2%
Ph phase_1
49
26%

Phase Distribution

53

Early Stage

100

Mid Stage

20

Late Stage

Phase Distribution180 total trials
Early Phase 1First-in-human
4(2.2%)
Phase 1Safety & dosage
49(27.2%)
Phase 2Efficacy & side effects
100(55.6%)
Phase 3Large-scale testing
9(5.0%)
Phase 4Post-market surveillance
11(6.1%)
N/ANon-phased studies
7(3.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.9%

95 of 134 finished

Non-Completion Rate

29.1%

39 ended early

Currently Active

33

trials recruiting

Total Trials

186

all time

Status Distribution
Active(34)
Completed(95)
Terminated(39)
Other(18)

Detailed Status

Completed95
Terminated36
Active, not recruiting17
unknown17
Recruiting16
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
186
Active
33
Success Rate
72.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (2.2%)
Phase 149 (27.2%)
Phase 2100 (55.6%)
Phase 39 (5.0%)
Phase 411 (6.1%)
N/A7 (3.9%)

Trials by Status

suspended11%
terminated3619%
active_not_recruiting179%
not_yet_recruiting11%
recruiting169%
completed9551%
unknown179%
withdrawn32%

Recent Activity

Clinical Trials (186)

Showing 20 of 186 trialsScroll for more
NCT06959771Phase 1

Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study

Recruiting
NCT05384756Phase 1

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Active Not Recruiting
NCT07599176Phase 1

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

Recruiting
NCT01729494Phase 4

Belatacept Early Steroid Withdrawal Trial

Completed
NCT07616154Phase 2

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

Recruiting
NCT03910452Early Phase 1

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Active Not Recruiting
NCT02629120Phase 1

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Active Not Recruiting
NCT01499888Phase 1

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

Active Not Recruiting
NCT03653338Phase 1

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Recruiting
NCT05501756Phase 2

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Recruiting
NCT06084780Phase 2

Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

Not Yet Recruiting
NCT05688436

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Active Not Recruiting
NCT06872333Phase 2

Allo HSCT for High Risk Hemoglobinopathies

Recruiting
NCT05463133Phase 1

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Recruiting
NCT03821610Phase 2

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Active Not Recruiting
NCT04339777Phase 2

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Recruiting
NCT03214354Phase 2

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Recruiting
NCT00977691Phase 1

Haploidentical PBMC Transplant for Severe Congenital Anemias

Active Not Recruiting
NCT03077542Phase 1

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Active Not Recruiting
NCT02472054Phase 1

Treatment of Familiar Lymphohistiocytosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
186